Shares of XBiotech Inc. (NASDAQ:XBIT – Get Free Report) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $7.45 and traded as high as $8.39. XBiotech shares last traded at $8.21, with a volume of 45,963 shares trading hands.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of XBiotech in a research note on Thursday, February 15th. They set a “sell” rating for the company.
Read Our Latest Research Report on XBiotech
XBiotech Stock Performance
XBiotech (NASDAQ:XBIT – Get Free Report) last announced its quarterly earnings results on Friday, March 15th. The biopharmaceutical company reported ($0.16) EPS for the quarter.
Hedge Funds Weigh In On XBiotech
An institutional investor recently bought a new position in XBiotech stock. National Bank of Canada FI acquired a new position in shares of XBiotech Inc. (NASDAQ:XBIT – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 24,347 shares of the biopharmaceutical company’s stock, valued at approximately $103,000. National Bank of Canada FI owned about 0.08% of XBiotech at the end of the most recent reporting period. 55.70% of the stock is owned by institutional investors and hedge funds.
XBiotech Company Profile
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Featured Stories
- Five stocks we like better than XBiotech
- Profitably Trade Stocks at 52-Week Highs
- Hasbro’s Management Made All the Right Calls This Quarter
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Canadian Penny Stocks: Can They Make You Rich?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.